The Company reported a net loss of approximately $8.4 million, or $0.25 per share, for the three months ended September 30, ...

Wong, Founder and CEO of HCW Biologics, stated, "In the third quarter 2024, the Company expanded our product portfolio and ...

P13, a biosimilar of infliximab, in inflammatory bowel diseases: a systematic review and meta-analysis," published in the November 2024 issue of Gastroenterology by Hu et al. Since 2015, CT-P13, a ...

THIS PIVOTAL election is completed and the people of New Hampshire have spoken. We are finally no longer “us and them” in ...